Career Development
Join UCSB's Office of Development on June 2nd & 16th to connect with UCSB Physics alumni for a facilitated Q&A about life during and after college with a degree in Physics.
Please join UCSB's Office of Development on June 2 and June 16 to connect with UCSB Physics âalumni for a facilitated Q&A about life during and after college with a degree in Physics. Register here (use the same link to register for either webinar).
Webinar 1
When: Tuesday, June 2 - 7:30PM
Who: David Hyde '13 (Math/Physics)
About David: David Hyde is a PIC Assistant Adjunct Professor in the Department of Mathematics at UCLA. He joined UCLA after graduate school at Stanford, where he earned a Ph.D. in Computer Science (focusing on computational physics and physically-based animation) and Masters degrees in computer science and applied math. At Stanford, Hyde was a National Defense Science and Engineering Graduate Fellow and Gerald J. Lieberman Fellow. Hyde earned a B.S. in Mathematics (and very nearly Physics!) as a Regents
Scholar at UCSB in 2013, graduating at age nineteen. Hyde has authored several patents in quantum computing (after studying the field at UCSB) and has also worked in industry for quantum computing and traditional software companies.
Webinar 2
When: Tuesday, June 16 - 5:30PM
Who: Dale Pfost '80 (Physics)
About Dale: Dale has 25 years experience as a life science entrepreneur, senior executive and venture investor. He has served as CEO of five biotechnology companies, three of which became publicly traded with valuations exceeding one billion dollars. Dale has successfully completed dozens of financings, overseen M&A transactions for nine companies, and served as a director at multiple public and private firms. He was founding CEO of Acuity Pharmaceuticals, which conducted the first-ever clinical trial with a gene silencing drug before merging to form OPKO Health. He was the founding CEO of Oxford GlycoSciences and genomics pioneer Orchid BioSciences, which completed IPOs in 1998 and 2000, respectively. Dale was CEO at anti-cancer company Receptor Bio Logix, where he led its successful acquisition by Symphogen. Dale's first company, which he started in graduate school, was acquired by SmithKline Beckman and produced the Biomek, still a leading laboratory automation system today. Before joining LODO, Dale was General Partner at venture capital partnership Advent Life Sciences and acting CEO of MicroBiome Therapeutics, which he co-founded. Dale is the co-author of 10 scientific papers and an inventor on 10 patents. He earned a BS from the University of California Santa Barbara and a PhD in physics from Brown University.